Business Context and Reporting Period
Company: CG Oncology, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: February 27, 2026
Reporting Period: This filing announces financial results for the year and quarter ended December 31, 2025. The specific financial data is contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. The filing references an attached press release (Exhibit 99.1) for details on:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide clear values for these metrics.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis of the 2025 results against prior periods.
Guidance, Outlook, and Risks
This 8-K filing serves as a notification of the results announcement. It does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies within the provided text. Such information is expected to be found in the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash burn figures for the year ended December 31, 2025.
- Verify the company's cash position and runway as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the company provided updated financial guidance for 2026 in the attached exhibit.